Firefly Neuroscience, Inc. (AIFF)

Firefly Neuroscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.23	2.14	0.06	0.65
Cash & Short-Term Investments	1.23	2.14	0.06	0.65
Cash Growth	37.74%	3594.83%	-91.12%	-
Other Receivables	0.09	0.08	0.02	0.04
Receivables	0.09	0.08	0.02	0.04
Prepaid Expenses	1.35	0.03	0.01	0.01
Total Current Assets	2.67	2.26	0.08	0.7
Property, Plant & Equipment	0.07	-	-	0.19
Other Intangible Assets	1.11	0.39	-	0
Other Long-Term Assets	1.47	-	0.05	0.06
Total Assets	5.31	2.64	0.14	0.95
Accounts Payable	1.38	0.46	0.42	0.5
Accrued Expenses	1.15	1.9	0.86	0.75
Short-Term Debt	-	0.18	0.18	2.26
Current Unearned Revenue	-	-	0.91	0.46
Total Current Liabilities	2.54	2.53	2.36	3.97
Total Liabilities	2.54	2.53	2.36	3.97
Additional Paid-In Capital	86.07	76.73	71.8	61.89
Retained Earnings	-83.3	-76.62	-74.02	-67.33
Total Common Equity	2.78	0.11	-2.23	-5.44
Shareholders' Equity	2.78	0.11	-2.23	-3.01
Total Liabilities & Equity	5.31	2.64	0.14	0.95
Total Debt	-	0.18	0.18	2.26
Net Cash (Debt)	1.23	1.97	-0.12	-1.6
Net Cash Per Share	0.04	0.06	-0.09	-
Filing Date Shares Outstanding	8.5	35.37	2.55	-
Total Common Shares Outstanding	8.48	35.37	2.55	-
Working Capital	0.13	-0.28	-2.28	-3.26
Book Value Per Share	0.33	0.00	-0.87	-
Tangible Book Value	1.67	-0.28	-2.23	-5.44
Tangible Book Value Per Share	0.20	-0.01	-0.87	-
Machinery	0.08	-	-	3.98

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q